Accelerant Holdings entered the most important two weeks of its short public life on August 13, 2026, when the company printed a strong second quarter and within hours announced a definitive agreement to be taken private by Thoma Bravo at $20.25 per share in cash, a 49% premium to the August 12, 2026 close of $13.59. The combination of a $1.32 billion Exchange Written Premium print, up 23% year-over-year, $93.1 million of Adjusted EBITDA, up 46% year-over-year, and a 30.6% Adjusted EBITDA margin landing in the same week as a $4 billion-plus take-private at a near-double premium is the load-bearing observation of the report. For a Cayman-domiciled, NYSE-listed risk exchange that only completed its IPO in July 2025, the Q2 print and the merger are not two separate events; they are the same event read in two registers. The operating story is what justified the premium, and the merger is what caps the public-market upside that the operating story would otherwise have unlocked.
The mechanism is straightforward and worth naming. Thoma Bravo, the world's largest software-focused investment firm with $172 billion of assets under management as of March 31, 2026, agreed to pay $20.25 in cash for every Class A and Class B common share of Accelerant, with a 6% per annum ticking fee that begins accruing after all conditions to closing are satisfied except the insurance regulatory approvals. The all-cash structure is not subject to a financing condition, Altamont Capital Partners, Accelerant's largest shareholder at approximately 82% of outstanding voting rights, has signed a voting and support agreement to approve the deal, and the transaction is expected to close in the first half of 2027. The market reaction, a single trading day price move from $13.59 to roughly the high teens, is the market repricing ARX from a public-market risk exchange multiple to a private-market strategic value anchored by Thoma Bravo's software and data thesis for specialty insurance distribution. We read this as the company being valued, in the buyer's frame, as a data and platform business, not as a specialty insurance underwriter.
The single load-bearing risk is regulatory and is not operational. The deal cannot close until specified insurance regulatory approvals are obtained, the Hart-Scott-Rodino waiting period expires, and certain foreign antitrust and foreign investment clearances are secured, and the company has disclosed that closing slippage attributable to insurance regulatory delay is the trigger for the ticking fee. The go-shop period runs through September 22, 2026, after which the company is subject to customary no-shop restrictions. The falsifiable clock is therefore the proxy filing, expected in the coming months, the shareholder vote, expected before the end of the first half of 2027, and the first insurance regulatory approval, which would unlock the ticking fee clock. A second falsifiable check is whether a Superior Proposal surfaces during the go-shop; the company has $56.9 million of break-fee exposure for a Superior Proposal signed with an Excluded Person and $136.5 million otherwise, a structure that discourages topping bids. The single number that frames the trade from here is therefore the spread between the current share price and $20.25 plus the time-value of the ticking fee, not the next quarter's earnings print, and Accelerant has explicitly suspended guidance and canceled the earnings call in light of the pending transaction.